Tuesday, August 11, 2026

Bitget Reports 18x Growth in rToken Trading Activity as Tokenized Markets Mature in July


VICTORIA, Seychelles - Monday, 10. August 2026

(GLOBE NEWSWIRE) -- Bitget, the world's largest Universal Exchange (UEX), has released its July 2026 Transparency Report, highlighting growing adoption of tokenized financial markets as users increasingly incorporated tokenized equities into broader trading and investment strategies. The report also outlines continued expansion across unified trading infrastructure, AI-powered investing, institutional products and onchain finance as tokenized assets become more deeply integrated into digital markets.

The month saw rToken surpassing US$100 million in assets under management within five weeks of launch, reaching approximately US$114 million by July 6. During the same period, cumulative trading volume reached US$671.37 million, including average daily trading volume of US$19.75 million, with more than 100,000 users trading rTokens. The report also found daily trading-user penetration increasing 18-fold from launch, while 42.87% of first-time buyers increased their positions within seven days, reflecting growing engagement beyond initial purchases.

Industry research published during the month reinforced Bitget’s position across trading infrastructure. CryptoRank found that Bitget recorded the lowest slippage for large tokenized equity trades and the highest balanced displayed liquidity within 50 basis points among the exchanges analysed. The CoinGlass 2026 Derivatives Market Report ranked Bitget second globally for ETH liquidity depth with US$81.37 million in order-book depth and fourth globally for BTC liquidity depth, while TokenInsight reported nearly US$70 billion in TradFi perpetual trading volume on Bitget during Q2 2026.

“Tokenized assets are only as strong as the market behind them. Investors don’t care how many assets an exchange lists if they can't trade them efficiently.," said Gracy Chen, CEO of Bitget. "DeFiLlama latest research shows that Bitget delivers the deepest liquidity and execution for tokenized equities among the exchanges evaluated. As adoption grows, that's what will decide which platforms investors continue to trust.”

Beyond market activity, Bitget continued to expand the infrastructure supporting tokenized finance. During July, the exchange enabled more than 100 tokenized U.S. stocks to be used as collateral within its Unified Trading Account, introduced GetAgent Playbook to extend AI-powered trading into tokenized investing, and released an institutional cross-asset collateral playbook exploring capital efficiency across crypto and tokenized assets.

Bitget Wallet also surpassed 100 million users, expanding stablecoin payment connectivity and tokenized asset access through new integrations including Robinhood Chain and Assetback. Beyond product development, Bitget expanded its Blockchain4Youth partnership with UNICEF's Game Changers Coalition from eight to eleven countries, extending blockchain, AI and financial literacy education to more young people worldwide.

The July Transparency Report reflects the continued evolution of tokenized markets as users increasingly integrate tokenized assets into active trading, portfolio management and cross-asset investing. The report reflects Bitget’s continued investment in market infrastructure, liquidity and institutional products, as tokenized finance becomes more integrated across retail and institutional markets.

To read the report, visit here.

About Bitget

Bitget is the world's largest Universal Exchange (UEX), serving over 125 million users and offering access to over 2M crypto tokens, 500+ tokenized stocks, ETFs, commodities, FX, and precious metals such as gold. The ecosystem is committed to helping users trade smarter with its AI agent, which co-pilots trade execution. Bitget is driving crypto adoption through strategic partnerships such as MotoGP™. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. Bitget currently leads in the tokenized TradFi market, providing the industry's lowest fees and highest liquidity across 150 regions worldwide.

For more information, visit: Website | X | Telegram | LinkedIn | Discord

For media inquiries, please contact: media@bitget.com

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ae92863f-91bb-49ee-bcab-2100ead8e0f4


Space42 signe un accord stratégique de 7 millions de dollars US avec Autonomous A2Z, pour accélérer le déploiement des solutions de mobilité autonome aux Émirats arabes unis

  • Ce premier accord commercial s'appuie sur le partenariat entre les deux entreprises pour accélérer les transports propulsés par l'IA

ABOU DHABI, Émirats arabes unis et SÉOUL, Corée du Sud - mardi, 11. août 2026

(GLOBE NEWSWIRE) -- Space42 (ADX : SPACE42), entreprise SpaceTech de nouvelle génération basée aux Émirats arabes unis et spécialisée dans les technologies spatiales de pointe propulsées par l’intelligence artificielle (IA), a conclu un accord stratégique avec Autonomous A2Z (A2Z), principale entreprise sud-coréenne spécialisée dans le développement de la technologie de conduite autonome. D’une valeur de 7 millions de dollars américains, cet accord vise à accélérer le deploiement des solutions de mobilité avancées de niveau 4 axées sur l’autonomie aux Émirats arabes unis, et constitue le premier accord commercial dans le cadre du partenariat plus large établi entre les deux entreprises. Sous forme d'un contrat d'approvisionnement direct, cet accord est complètement distinct de la co-entreprise annoncée en 2025, visant à soutenir la commercialisation à long terme des solutions de mobilité intelligente aux Émirats arabes unis.

L'accord associe la technologie éprouvée en matière de conduite autonome de niveau 4 d'A2Z aux capacités de pointe de Space42 en matière d'IA, des technologies géospatiales et de connectivité. Pour A2Z, cette étape représente une étape majeure dans sa stratégie d'expansion internationale, lui permettant de déployer la technologie de conduite autonome développée en Corée sur l'un des marchés de la mobilité intelligente à la croissance la plus rapide au monde. Pour Space42, l’accord vient renforcer une priorité stratégique convoitée par l'entreprise dans ce secteur : favoriser et garantir les opérations sûres et fiables des véhicules autonomes à grande échelle.

Hasan Al Hosani, PDG de la division Smart Solutions chez Space42, a déclaré : « La mobilité autonome constitue un pilier central au développement des villes intelligentes. Les Émirats arabes unis ont mis en place les conditions réglementaire, technologique et d'infrastructure de pointe pour intégrer la mobilité autonome dans les transports du quotidien. Notre objectif est clair : de transformer cette ambition en un service fiable, sûr et accessible capable d’offrir aux usagers au quotidien un transport fluide et sans effort, s’appuyant sur des normes de sécurité strictes de classe mondiale. Notre collaboration avec A2Z s’inscrit pleinement dans cette ambition et contribue à nos efforts pour établir un modèle de transport moderne qui répond aux besoins des Émirats arabes unis, tout en accompagnant l’évolution rapide du marché en matière de transport. »

Han Ji-hyung, PDG d'Autonomous A2Z, a déclaré : « Cet accord stratégique démontre de la capacité des technologies de conduite autonome développées et validées en Corée à être déployées sur les marchés internationaux. Avec Space42, nous sommes impatients d'apporter nos solutions éprouvées en matière de mobilité autonome aux Émirats arabes unis et de soutenir notre expansion sur les marchés mondiaux. »

Les services pilotes de Robo-Shuttle (navettes autonomes à la demande), utilisant le véhicule autonome « ROii » d'A2Z, ainsi que sur d'autres véhicules autonomes modifiés et rétrofités, feront l'objet de plusieurs phases de tests opérationnels et d'évaluation de la demande, suivis d’une expansion vers les services de transport à la demande (Demand-Responsive Transport – DRT), et l’opération de navettes touristiques. Ce déploiement progressif permettra de recueillir des informations opérationnelles précieuses en conditions réelles, afin de soutenir l’extension future de ces solutions à d'autres cas d'utilisation dans le domaine du transport.

Soutenir la vision d’une mobilité urbaine intelligente aux Émirats arabes unis

Le projet s'inscrit dans la vision des Émirats arabes unis visant à promouvoir les solutions de transport intelligent propulsées par l'IA et la mobilité intelligente autonome, conformément aux ambitions de la Stratégie Nationale de Mobilité Intelligente. Le projet s'appuie également sur le portefeuille de solutions de mobilité géré par Space42, dont TXAI, le premier service de taxi autonome aux Émirats arabes unis, ayant parcouru plus de 600 000 kilomètres sur 20 000 trajets sans aucun accident enregistré depuis son lancement en 2021.

Mettre en lumière la technologie de conduite autonome sud-coréenne sur la scène mondiale

Cet accord marque l'un des plus grands déploiements sur les marchés internationaux jamais réalisés par A2Z, illustrant la compétitivité mondiale de la technologie sud-coréenne en matière de conduite autonome. Avec une flotte de 91 véhicules autonomes autorisés, l’entreprise a mené des essais de conduite autonome dans 13 villes et provinces en Corée, franchisant le cap des 1,02 million de kilomètres cumulés parcourus en conduite autonome en environnement urbain. Cette expérience s’appuie sur une expertise intégrée, couvrant la conception de logiciels, l'intégration des véhicules, l'exploitation des flottes, ainsi que la gestion des services.

Cette avancée fait suite à plusieurs années de collaboration entre la Corée et les Émirats arabes unis, portée par des initiatives gouvernementales visant à favoriser l’innovation technologique et les tests, et à accélérer l'accès aux marchés. L'exécution commerciale a été assurée par A2G (Autonomous to Global), une co-entreprise basée à Singapour, réunissant A2Z et Kilsa Global.

À propos de Space42

Space42 (ADX : SPACE42) est une société spécialisée dans la technologie de l’espace basée aux Émirats arabes unis, qui intègre les communications par satellite, l’analyse géospatiale et les capacités d’intelligence artificielle pour informer la Terre depuis l’espace. Créée en 2024 à la suite de la fusion réussie de Bayanat et Yahsat, Space42 bénéficie d’une envergure mondiale qui lui permet de répondre aux besoins en constante évolution des gouvernements, des entreprises et des communautés à travers le monde. Space42 comprend deux unités commerciales : Space Services et Smart Solutions. La division Space Services se consacre aux opérations de satellites en amont pour la fourniture de services de connectivité fixe et mobile par satellite. La division Smart Solutions conjugue l’acquisition et le traitement de données géospatiales aux capacités de l’intelligence artificielle pour éclairer la prise de décision, approfondir la connaissance situationnelle et optimiser l’efficacité opérationnelle des organisations. Parmi les principaux actionnaires de Space42 figurent G42, Mubadala et IHC.

Pour en savoir plus, rendez-vous sur le site www.space42.ai; ou suivez-nous sur LinkedIn : Space4.
Pour toute demande d’information destinée aux investisseurs : ir@space42.ai.

À propos de Autonomous A2Z

Fondée en 2018 par quatre anciens ingénieurs de Hyundai Motor, Autonomous A2Z est une start-up sud-coréenne spécialisée dans le développement de technologies de conduite autonome de niveau 4 et s’impose aujourd’hui comme l’un des acteurs de référence en Corée du Sud dans le domaine des solutions de mobilité autonome. Avec une flotte de 91 véhicules autonomes, la plus importante de Corée du Sud, Autonomous A2Z a franchisé le cap des 1,02 million de kilomètres cumulés parcourus en conduite autonome en environnement urbain, établissant un record national qui témoigne de la maturité de ses technologies en conditions réelles. Forte de cette expertise, A2Z développe une gamme de solutions de mobilité du futur, notamment des navettes urbaines autonomes et des solutions de mobilité logistique intelligentes, se positionnant ainsi à l’avant-garde de la commercialisation de technologies de conduite autonome sûres et performantes. En 2024, A2Z a finalisé le développement de son véhicule autonome de niveau 4, ROii, et prévoit d'entamer en 2026 les différentes étapes de certification et de validation de ses performances, ouvrant ainsi la voie à la commercialisation à grande échelle de ce véhicule. Parallèlement, l’entreprise accélère son expansion à l’international, en renforçant ses activités à Singapour, aux Émirats arabes unis et au Japon. A2Z poursuit également le développement d’initiatives en faveur d’une mobilité plus inclusive et durable, notamment des services de mobilité destinés à améliorer l’accessibilité aux transports, ainsi que des solutions logistiques intelligentes fondées sur les technologies de conduite autonome.

Avis juridique et mise en garde relative aux déclarations prospectives

Le présent communiqué de presse peut contenir des déclarations prospectives fondées sur les attentes et hypothèses actuelles concernant des événements futurs. Ces déclarations prospectives peuvent être identifiées à l'aide de la terminologie prospective, notamment des termes tels que « prévoir », « sera » et/ou, dans chaque cas, d'autres variantes ou terminologie comparable. De par leur nature, les déclarations prospectives impliquent des risques et des incertitudes et peuvent s’avérer inexactes. Elles reflètent les données et informations disponibles à la date de leur publication et les entreprises déclinent toute obligation de mise à jour. En conséquence, aucune assurance raisonnable ne peut être donnée quant à la réalisation de ces déclarations prospectives, et il convient de ne pas s’y fier indûment. Le présent communiqué de presse ne constitue pas ni une offre, ni une recommandation en vue de l’achat, de la souscription ou de la vente de titres financiers dans quelque juridiction que ce soit, et ne doit pas être interprété comme une communication promotionnelle à caractère financier.

Une photo annexée au présent communiqué est disponible à l’adresse suivante : http://www.globenewswire.com/NewsRoom/AttachmentNg/d243d30d-6105-4e0d-8c0d-cb05c552df44


Space42 and Autonomous A2Z Sign US$7 Million Agreement to Deploy Autonomous Mobility Solutions in the UAE

  • First commercial agreement builds on the companies’ partnership to accelerate AI-powered transportation

ABU DHABI, United Arab Emirates and SEOUL, South Korea - Monday, 10. August 2026

(GLOBE NEWSWIRE) -- Space42 (ADX: SPACE42), the UAE-based AI-powered SpaceTech company, and Autonomous A2Z (A2Z), South Korea’s leading autonomous driving company, have signed a commercial agreement valued at US$7 million to deploy Level-4 mobility solutions in the UAE. This is the first commercial agreement in the two companies’ broader partnership. It is a direct supply contract, separate from the joint venture announced in 2025 to support the long-term commercialization of intelligent mobility solutions in the UAE.

The agreement combines A2Z’s proven Level-4 autonomous driving technology with Space42’s AI, geospatial, and connectivity capabilities. For A2Z, the milestone represents a significant step in its international expansion strategy, bringing Korean-developed autonomous driving technology to one of the world’s fastest-growing smart mobility markets. For Space42, it advances the company's sectorial priority to enable safe and reliable driverless vehicle operations at scale.

Hasan Al Hosani, CEO of Smart Solutions at Space42, said: “Autonomous mobility is critical infrastructure for smart city development. The UAE has created the conditions for its integration within everyday transport, and our focus is to turn that ambition into a dependable service that moves people seamlessly, aligned with world-class safety standards. Working with A2Z brings us closer to establishing a model that serves the UAE and responds to the market’s changing transport needs.”

Han Ji-hyung, CEO of Autonomous A2Z, stated: “This agreement demonstrates that autonomous driving technology developed and validated in Korea is ready for international deployment. Together with Space42, we look forward to bringing proven autonomous mobility solutions to the UAE and expanding into global markets.”

Pilot Robo-Shuttle services using A2Z’s ‘ROii’, alongside other modified and retrofitted autonomous vehicles, will undergo operational testing and demand assessment, followed by an expected expansion into Demand-Responsive Transport (DRT) and tourism shuttle operations. The phased rollout will provide invaluable road-based operational insights, to support future growth across additional transport use cases.

Supporting the UAE’s smart mobility vision

The project aligns with the UAE’s broader vision to advance AI-enabled transportation and intelligent mobility, as part of its National Smart Mobility Strategy. The project also builds on Space42’s portfolio of mobility solutions, including TXAI, an autonomous taxi service that has traveled more than 600,000 kilometers across 20,000 trips with zero recorded accidents since operations began in 2021.

Demonstrating South Korean autonomous driving technology on the global stage

The agreement marks one of A2Z’s largest international deployments, demonstrating the global competitiveness of South Korea’s autonomous driving technology. The company has conducted autonomous driving trials across 13 cities and provinces in Korea and operates 91 permitted autonomous vehicles with more than 1.02 million kilometers of cumulative driving experience, spanning software development, vehicle integration, fleet operations, and service management.

The development follows several years of collaboration between Korea and the UAE, supported by government initiatives in technology development, testing, and market entry. Commercial execution was led by A2G (Autonomous to Global), A2Z’s Singapore-based joint venture with Kilsa Global.

About Space42

Space42 (ADX: SPACE42) is a UAE-based AI-powered SpaceTech company that integrates satellite communications, geospatial analytics and artificial intelligence capabilities to enlighten the Earth from space. Formed in 2024 by the merger of Bayanat and Yahsat, Space42’s global reach allows it to address the rapidly evolving needs of its customers in governments, enterprises, and communities. Space42 comprises two business units: Space Services and Smart Solutions. Space Services focuses on upstream satellite operations for both fixed and mobility satellite services. Smart Solutions integrates geospatial data acquisition and processing with AI to inform decision-making, enhance situational awareness, and improve operational efficiency. Major shareholders include G42, Mubadala and IHC.

For more information, visit: www.space42.ai; follow us on LinkedIn: Space42 For investor inquiries, please contact: ir@space42.ai

About Autonomous A2Z

Founded in 2018 by four former Hyundai Motor autonomous driving engineers, Autonomous A2Z is South Korea’s leading autonomous driving solutions company. The company operates the largest fleet of 91 autonomous vehicles in S.Korea and has achieved the country’s longest cumulative urban driving record of approximately 1,020,000 kilometers. Building on this experience, A2Z is developing a range of future mobility services, including urban autonomous shuttles and smart logistics mobility solutions, leading the commercialization of safe and efficient autonomous driving technologies. In 2024, A2Z completed the development of its Level-4 autonomous vehicle, ROii, and plans to begin performance certification and validation in 2026, paving the way for full-scale commercialization. The company is actively expanding its business across Singapore, the UAE, and Japan, and continues to drive sustainable mobility innovation through initiatives such as mobility services for transportation accessibility and smart logistics solutions leveraging autonomous driving technology.

Legal Notice and Cautionary Statement Regarding Forward-Looking Information

This announcement may contain forward-looking statements based on current expectations and assumptions about future events. These statements—identified by terms such as “expect,” “will,” or similar—are subject to risks and uncertainties and may prove inaccurate. They reflect information available as of the date hereof, and the companies disclaim any obligation to update them. No assurance is given that any forward-looking statement will occur, and undue reliance should not be placed on them. This announcement does not constitute a financial promotion or an offer to buy or sell securities in any jurisdiction.

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d243d30d-6105-4e0d-8c0d-cb05c552df44


Monday, August 10, 2026

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

SAN CARLOS, Calif. & REDWOOD CITY, Calif. - Monday, 10. August 2026


Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancers


Regional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets


(BUSINESS WIRE) -- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets.


Clinical collaboration will explore potential targeted combination approaches for patients with RAS-addicted cancers


Potential drug combinations for development as part of the clinical collaboration will include certain BeOne assets and Revolution Medicines’ four clinical RAS(ON) inhibitors: daraxonrasib, a RAS(ON) multi-selective inhibitor; zoldonrasib, a RAS(ON) G12D-selective inhibitor; elironrasib, a RAS(ON) G12C-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor. Planned combination studies include: BeOne’s MTA-cooperative PRMT5 inhibitor, BGB-58067, and an EGFR x MET x MET trispecific antibody, BG-T187, with either daraxonrasib or zoldonrasib.


Regional rights agreement leverages BeOne’s established R&D and commercial expertise and Revolution Medicines’ clinical stage RAS(ON) inhibitor portfolio


Under the regional rights agreement, Revolution Medicines has granted BeOne exclusive rights in select Asian markets to develop and commercialize or solely commercialize, depending on the market, these four clinical-stage RAS(ON) inhibitors. Revolution Medicines is eligible to receive development and sales milestone payments and tiered royalties on net sales in the partnered region. Revolution Medicines retains development and commercial rights to all its assets outside of the licensed territory, including Japan and South Korea. As part of this multi-part arrangement, BeOne will fund and conduct a global registrational Phase 3 study for one of Revolution Medicines RAS(ON) inhibitors using BeOne’s differentiated, fully in-house development superhighway, while Revolution Medicines continues to advance a broad range of global registrational studies across its portfolio.


John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said:

“We are pleased to enter this collaboration with Revolution Medicines, which gives BeOne the opportunity to evaluate combinations between assets from our oncology pipeline and four promising RAS(ON) inhibitors from Revolution Medicines. In parallel, the regional rights transaction allows us to use our global development superhighway capabilities and established commercial presence, with the goal of bringing more medicines to patients with difficult-to-treat cancers.”


Mark A. Goldsmith, M.D., Ph.D., CEO and Chairman of Revolution Medicines, said:

“This arrangement with BeOne reflects our commitment to advancing RAS(ON) inhibitors for patients with RAS-addicted cancers around the world, including in regions where we have not previously had a presence, while exploring novel combination strategies that may further expand their potential impact. BeOne brings additional established global oncology development capabilities and a strong regional commercial footprint that can help us broaden the reach of our innovative RAS(ON) inhibitors as part of our ambitious global strategy.”


About BeOne


BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.


To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.


About Revolution Medicines


Revolution Medicines is a late-stage clinical oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit www.revmed.com and follow Revolution Medicines on LinkedIn, X (Twitter) and Instagram.


For more information, please visit www.revmed.com.


BeOne Medicines Forward-Looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne’s and Revolution Medicines’ plans, expectations and goals for their strategic collaboration and regional rights transaction; the potential to evaluate and develop combination therapies involving select BeOne assets and Revolution Medicines’ RAS(ON) inhibitors; BeOne’s development and commercialization activities in select Asian markets; Revolution Medicines’ global portfolio strategy; and the potential benefits of the agreement for patients with RAS-addicted cancers. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including each company’s ability to: successfully execute its obligations under the agreement; demonstrate the efficacy and safety of its drug candidates; generate clinical results that support further development or marketing approval; obtain regulatory approvals and achieve commercial success, if approved; obtain and maintain intellectual property protection; rely on third parties for drug development, manufacturing, commercialization and other services; and other risks more fully discussed in each company’s filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and neither company undertakes any duty to update such information unless required by law.


Revolution Medicines Forward-Looking Statements


This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding Revolution Medicines plan to evaluate and develop combination therapies through the collaboration with BeOne Medicines, including potential combinations, funding and expected benefits from any such development; milestone payments, sales milestone payments and tiered royalties on net sales that Revolution Medicines may receive under the collaboration with BeOne Medicines; Revolution Medicines’ development opportunities, plans and timelines and its ability to build or advance its portfolio and R&D pipeline; the progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of Revolution Medicines’ candidates being studied; Revolution Medicines’ ability to discover and develop approaches that improve outcomes for patients with RAS-addicted cancers; and plans for developing any of Revolution Medicines’ product candidates as part of a combination treatment.


Forward-looking statements are typically, but not always, identified by the use of words such as “aims,” “anticipate,” "believe," "estimate," "expect," "plan," “potential,” “project,” “up to,” "will" and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause Revolution Medicines’ development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Revolution Medicines’ programs’ development stages, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, commercialization preparation and launch readiness, Revolution Medicines’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Revolution Medicines’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on Revolution Medicines’ business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 5, 2026, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260810801799/en/



Permalink

https://www.aetoswire.com/en/news/1008202656672


Contacts

BeOne Medicines Media & Investor Contacts:


Investor Contact

Liza Heapes

+1 857-302-5663

ir@beonemed.com


Media Contact

Kyle Blankenship

+1 667-351-5176

media@beonemed.com


To access BeOne media resources, please visit our Newsroom.


Revolution Medicines Media & Investor Contacts:

media@revmed.com

investors@revmed.com

Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets

MUNICH - Friday, 07. August 2026

(BUSINESS WIRE)--2Q 2026

Total business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth.

    Operating profit rises 10.6 percent to a record level of 4.9 billion euros.
    Shareholders’ core net income at 2.6 billion euros; 12.7 percent below last year. Adjusted for a divestment gain last year and offsetting measures following the sale of the stake in our Indian JVs, underlying growth is strong at 10 percent.

6M 2026

    Total business volume at 98.6 billion euros, an internal growth of 4.3 percent1, driven by Property-Casualty and especially Asset Management.
    Operating profit rises 8.6 percent and reaches a record level of 9.4 billion euros.
    Shareholders’ core net income advances 15.5 percent to 6.4 billion euros. Adjusted for divestment effects and offsetting measures, underlying growth is strong at 9 percent2.
    Core earnings per share increase 17.5 percent and reach 16.44 euros. Adjusted for the above-mentioned effects, underlying growth is excellent at 10 percent 2 .
    Annualized core RoE at 20.7 percent; underlying level very strong at 19 percent 2 .
    Solvency II ratio3 increases by 7 percentage points to 225 percent4. Capital generation remains very good.

Outlook & other

    Allianz is fully on track to achieve its full-year operating profit outlook of 17.4 billion euros, plus or minus 1 billion euros5.
    Share buy-back program of up to 2.5 billion euros announced on February 25, 2026 underway; 1.4 billion euros completed in the first half of 2026.

CEO comment

"Allianz has once more delivered strong results for the second quarter and first half of 2026, confirming the power of our customer-centered strategy. Our excellent performance gives us the ability – as well as the obligation – to bring superior advice, protection, and retirement solutions within reach for more customers around the world.

Insurance costs are rising faster than disposable income, and we take that challenge seriously. Through our investments in AI, risk prevention, and smarter services, we are determined to help more customers protect what matters to them at a price they can afford. This value creation is how Allianz earns the trust that sets us apart and drives our growth."

- Oliver Bäte, Chief Executive Officer of Allianz SE

View full article here: https://www.aetoswire.com/en/news/7082026566511

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260806509750/en/

Permalink
https://www.aetoswire.com/en/news/7082026566511

Contacts

Media contacts
Frank Stoffel Tel. +49 160 9011 5157 e-mail: frank.stoffel@allianz.com
Ann-Kristin Manno Tel. +49 151 2990 1517 e-mail: ann-kristin.manno@allianz.com
Johanna Oltmann Tel. +49 151 1164 6551 e-mail: johanna.oltmann@allianz.com
Fabrizio Tolotti Tel. +49 151 5995 6396 e-mail: fabrizio.tolotti@allianz.com

Investor Relations contacts
Andrew Ritchie Tel. +49 89 3800 3963 e-mail: andrew.ritchie@allianz.com
Reinhard Lahusen Tel. +49 89 3800 17224 e-mail: reinhard.lahusen@allianz.com
Christian Lamprecht Tel. +49 89 3800 3892 e-mail: christian.lamprecht@allianz.com
Tobias Rupp Tel. +49 89 3800 7151 e-mail: tobias.rupp@allianz.com

Sunday, August 9, 2026

ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings

 VIENNA - Saturday, 08. August 2026 AETOSWire Print 



(BUSINESS WIRE)--An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accrue until PharmaEssentia has made payment. All of PharmaEssentia’s remaining claims of the quantum stage of the proceedings were dismissed.


The decision follows the partial final award received in February 2025, in which the ICC Arbitral Tribunal found, among other things, that PharmaEssentia had intentionally breached its contractual obligations and was liable for several claims arising out of the parties’ licensing agreement. The quantum award now determines the amounts due in relation to these claims.


Tribunal confirms PharmaEssentia’s excessive pricing of up to 900%


Applying the Tribunal’s reasoning in the quantum award to the product deliveries for the years 2023-2025, PharmaEssentia has overcharged AOP Health by another ca. EUR 65 Mio. After set-off with profit sharing amounts for these years, PharmaEssentia will still owe a substantial amount to AOP Health. In short, AOP Health owes no payment to PharmaEssentia. Meanwhile, PharmaEssentia’s liability towards AOP Health is currently in the three-digit EUR million range.


Safeguarding Patient Access


AOP Health welcomes the decision, which the company sees as a further confirmation of its position and its conduct in the proceedings. The company remains focused on ensuring stable and sustainable access to BESREMi® for patients in need. In its seventh year after its approval by European Medicines Agency (“EMA”), AOP Health has successfully made BESREMi® available to an estimated 12,600 patients in AOP Health’s licensed territory.


Dr. Rudolf Widmann, one of the two founders of AOP Health, says: “After eight years of legal dispute, we welcome the tribunal’s decision because it reduces uncertainty. This award gives us a stronger basis to continue our mission: developing and making available medicines that address high unmet medical needs.”


As with the previous award, PharmaEssentia may seek a limited review of the quantum award before the competent German courts. Proceedings concerning the review of the February 2025 merit award which was confirmed by the Higher Regional Court of Frankfurt in April 2026 are still pending before the German Federal Court of Justice.


Background to the dispute


The conflict concerns BESREMi®, a treatment for rare blood cancers, particularly polycythemia vera. AOP Health acquired the rights for the development and commercialization of BESREMi® in the European, Commonwealth of Independent States (CIS), and Middle Eastern markets from PharmaEssentia in 2009.


Since 2017, PharmaEssentia has repeatedly attempted to terminate its agreement with AOP Health regarding BESREMi®. In October 2020, an ICC Arbitral Tribunal rejected these attempts and awarded AOP Health damages, while dismissing PharmaEssentia’s counterclaims. Subsequent set-aside proceedings confirmed the award in its essentials, while identifying procedural issues relating to the quantification of damages.


In November 2020, PharmaEssentia initiated a further legal action against AOP Health, alleging damage claims. AOP Health in turn claimed damages for delays in BESREMi®’s European approval caused by PharmaEssentia and for the use of AOP Health’s clinical trial data in connection with PharmaEssentia’s U.S. marketing authorization. In February 2025, the ICC Arbitral Tribunal issued a partial final award in AOP Health’s favor on liability and dismissed PharmaEssentia’s liability claims in its entirety. The newly received quantum award now specifies the amounts due for the claims upheld in the partial final award.


About BESREMi®


BESREMi® is the first interferon that was approved for polycythemia vera, a myelo­proliferative neoplasm (MPN), indicated in the European Union as monotherapy in adults for treatment of polycythemia vera without symptomatic enlarged spleen. Its overall safety and efficacy were demonstrated in multiple clinical studies.


BESREMi® (ropeginterferon alfa-2b) is a long-acting, mono-pegylated proline interferon (ATC L03AB15). It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization of blood values. BESREMi® is designed to be self-administered subcutaneously with a pre-filled pen.


Please visit: European Medicines Agency Summary of Product Characteristics for: BESREMi®


About AOP Health


AOP Health Group is a global pharmaceutical enterprise with headquarters in Vienna. Its mission is to address high unmet medical needs through impactful, science-driven therapies and care models. Since 1996, AOP Health has pioneered research where limited therapies exist, to develop solutions for patients with rare diseases and severe conditions in niche therapeutic areas. Guided by the principle "Needs. Science. Trust.” the AOP Health Group demonstrates its strong commitment to patients and healthcare professionals through innovation and long-term partnerships, to improve patient outcomes worldwide.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260807889741/en/



Permalink

https://www.aetoswire.com/en/news/8082026566633


Contacts

Isolde Fally

Corporate Communications Manager

Isolde.Fally@aop-health.com

+43 676 500 4048

Energy Vault Announces Strategic Agreement to Deploy 1.25 GW of Integrated Power Infrastructure for Hyperscaler AI Data Center with Leading Power Generation EPC Deploying Caterpillar Gensets

 


WESTLAKE VILLAGE, Calif. - 

Partnership combines Energy Vault's FEOC-compliant BESS, grid-forming PCS, and AI infrastructure control software with partner’s turnkey power generation, Caterpillar gensets and EPC capabilities


Reference architecture delivers firm grid-independent power, essential grid stabilization and load balancing to deliver modular, scalable, gigawatt-scale AI campuses with "always-on" availability


Second strategic framework agreement together advances Energy Vault's AI infrastructure strategy and establishes a repeatable “speed-to-power” deployment platform


Initial 1.25 GW is backed by a hyperscaler customer contract for deployment in Texas


Energy Vault expects a revenue impact of ~$500 - $600 million in 2H 2026 and 2027, which will be discussed during the upcoming earnings call on August 11, 2026


 


(BUSINESS WIRE)--Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a global leader in sustainable energy infrastructure, today announced the execution of a strategic commercial agreement under which Energy Vault will supply battery energy storage systems ("BESS"), grid-forming power conversion systems and AI infrastructure control software to support an initial deployment totaling 1.25 gigawatts ("GW") of integrated power infrastructure for hyperscaler AI data centers.


The agreement establishes a repeatable AI power infrastructure platform that combines dispatchable power generation, intelligent battery energy storage, grid-forming inverter systems, advanced AI infrastructure controls software and turnkey EPC and plant integration into a single integrated solution designed specifically for hyperscaler AI data centers and high-performance computing campuses.


The companies will jointly deploy fully integrated, off-grid power systems capable of bringing AI compute capacity online significantly faster than traditional utility interconnection schedules while providing the reliability, resiliency and operational flexibility required by next-generation AI workloads.


Initial deployments are expected over the next four to twelve months, supporting an accelerated speed-to-power schedule that is not dependent on traditional utility interconnection timelines.


As hyperscaler AI infrastructure continues to expand globally, developers increasingly require complete power infrastructure platforms rather than individual technologies. AI computing loads can change rapidly as GPU clusters ramp up and down, creating demanding transient, voltage, frequency and power-quality requirements that generation assets alone may not efficiently manage.


The integrated solution has been specifically designed to address these requirements through a fully integrated architecture that intelligently coordinates generation, energy storage and site-wide electrical infrastructure in real time. The solution is designed to support FEOC-compliant deployments while providing a repeatable reference architecture for integrated digital control, power distribution, grid stabilization and active load optimization.


Unlike traditional deployments where individual assets operate independently, the integrated platform continuously orchestrates and optimizes the generation, battery storage, power conversion, redundancy systems and electrical infrastructure as a single intelligent power plant.


Energy Vault's AI infrastructure controls software functions as a mission-critical operating system for the site's power infrastructure, dynamically balancing power flows, maintaining voltage and frequency stability, minimizing generator cycling, improving fuel efficiency and ensuring the rapid response required by highly dynamic AI compute environments.


The modular architecture also enables customers to deploy AI infrastructure ahead of permanent grid interconnection, while providing the flexibility to integrate utility power, renewable generation and additional distributed energy resources as campus requirements expand.


The national turnkey power generation engineering, procurement and construction ("EPC") contractor contributes decades of experience delivering complex generation projects across natural gas reciprocating engines, gas turbines, diesel generation, solar PV and emerging hydrogen technologies. Energy Vault complements these capabilities with one of the industry's broadest portfolios of utility-scale battery energy storage systems, intelligent energy management software and hybrid power plant integration expertise developed across projects worldwide.


"Artificial intelligence is fundamentally changing how critical power infrastructure is designed, deployed and operated," said Robert Piconi, Chairman and Chief Executive Officer of Energy Vault. "Customers are no longer procuring individual technologies—they require integrated power infrastructure capable of delivering reliable, always-on electricity at unprecedented speed and scale. With this agreement we have created a highly differentiated platform that combines industry-leading power generation, intelligent energy storage and advanced power plant software into a single integrated solution purpose-built for AI infrastructure.


"As our largest single contract executed to date, this milestone agreement represents another important step in Energy Vault's strategic evolution from an energy storage technology pioneer into an integrated energy infrastructure provider. More importantly, it establishes a repeatable commercial platform that we believe can support substantial future expansion as hyperscaler AI infrastructure investments continue to accelerate globally."


A senior executive at Energy Vault’s strategic power infrastructure partner commented, "Energy Vault's BESS, grid-forming technology and software platform are central to this solution. By integrating those systems into our modular plant design, we can bring large blocks of dependable power online quickly while maintaining the performance, scalability and flexibility that hyperscale campuses require."


The companies intend to jointly pursue additional hyperscaler, neocloud and AI infrastructure opportunities in markets where constrained grid capacity, extended utility interconnection timelines and increasing electricity demand are driving the need for rapidly deployable behind-the-meter and bridge-power solutions. The partnership is designed as a scalable commercial platform capable of supporting significant future expansion beyond the initial contracted deployment.


About Energy Vault


Energy Vault® develops, deploys and operates utility-scale energy storage solutions designed to transform the world’s approach to sustainable energy storage. The Company’s comprehensive offerings include proprietary battery, gravity and green hydrogen energy storage technologies supporting a variety of customer use cases delivering safe and reliable energy system dispatching and optimization. Each storage solution is supported by the Company’s technology-agnostic energy management system software and integration platform. Unique to the industry, Energy Vault’s innovative technology portfolio delivers customized short, long and multi-day/ultra-long duration energy storage solutions to help utilities, independent power producers, large industrial energy users, and AI/cloud infrastructure companies significantly reduce levelized energy costs while maintaining power reliability. Please visit www.energyvault.com for more information.


Forward-Looking Statements


This press release includes forward-looking statements that reflect the Company’s current views with respect to, among other things, the Company’s operations and financial performance. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as “anticipate,” “expect,” “contemplate,” “continue,” “suggest,” “plan,” “potential,” “predict,” “believe,” “intend,” “project,” “forecast,” “estimate,” “target,” “project,” “projections,” “should,” “target,” “could,” “would,” “may,” “might,” “will” and other similar expressions. We base these forward-looking statements or projections on our current expectations, plans and assumptions, which we have made in light of our experience in our industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at the time. These forward-looking statements are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. These forward-looking statements are only predictions based upon our current expectations and projections about future events. These forward-looking statements involve significant risks and uncertainties that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including changes in our strategy, expansion plans, customer opportunities, future operations, future financial position, estimated revenues and losses, expected monetization of tax credits, expected financings, projected costs, prospects and plans; the uncertainty of our awards, bookings, backlog and developed pipeline equating to future revenue; our ability to successfully provide AI power infrastructure and secure additional AI power infrastructure work; the lack of assurance that non-binding letters of intent and other indications of interest can result in binding financings, orders or sales; the possibility of our products or services to be or alleged to be defective or experience other failures; the implementation, market acceptance and success of our business model and growth strategy; our ability to develop and maintain our brand and reputation; developments and projections relating to our business, our competitors, and industry; the impact of macroeconomic uncertainty, including with respect to uncertainty about the future relationship between the United States and other countries with respect to trade policies and tariffs; changes in tax laws and government regulations and the impact of those changes on us, including as a result of the One Big Beautiful Bill Act and its changes to the Internal Revenue Code of 1986, as amended and the clean-energy tax credits established under the Inflation Reduction Act of 2022; investment in development projects that may not achieve commercial operations in our predicted timeframe or at all; our efforts to diversify our supply chain to lessen the impact of tariffs; the ability of our suppliers to deliver necessary components or raw materials for construction of our energy storage systems in a timely manner; our expectations regarding our ability to obtain and maintain intellectual property protection and not infringe on the rights of others; our future capital requirements and sources and uses of cash; developments in U.S. and global trade policy; the international nature of our operations and the impact of war or other hostilities on our business and global markets; our ability to obtain funding for our operations and future growth; and our business, expansion plans and opportunities, including our expansion into owned and operated projects; and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 18, 2026, as such factors may be updated from time to time in its other filings with the SEC, accessible on the SEC’s website at www.sec.gov. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Any forward-looking statement made by us in this press release speaks only as of the date of this press release and is expressly qualified in its entirety by the cautionary statements included in this press release. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable laws. You should not place undue reliance on our forward-looking statements.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260807600552/en/



Permalink

https://aetoswire.com/en/news/8082026566622


Contacts

Energy Vault:

Investors energyvaultIR@icrinc.com

Media media@energyvault.com